+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Insulin Market Research Report by Drug (Biologic and Biosimilar), by Application (Type I Diabetes and Type II Diabetes), by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 5337609
  • Report
  • July 2021
  • Region: Global
  • 183 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Insulin Market will Grow to USD 66.81 Billion by 2026, at a CAGR of 12.99%

FEATURED COMPANIES

  • Adocia
  • Biocon Limited
  • Eli Lilly and Company
  • Julphar
  • Merck & Co.
  • Oramed Pharmaceuticals
  • MORE
The Global Insulin Market size was estimated at USD 32.09 Billion in 2020 and expected to reach USD 36.16 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 12.99% to reach USD 66.81 Billion by 2026.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Insulin to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug, the Insulin Market was studied across Biologic and Biosimilar.
  • Based on Application, the Insulin Market was studied across Type I Diabetes and Type II Diabetes.
  • Based on Region, the Insulin Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Insulin Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Insulin Market, including Adocia, AstraZeneca PLC, B. Braun Melsungen AG, Becton, Dickinson and Company, Biocon Limited, Biodel Inc., Bioton SA, Dongbao Enterprise Group Co., Ltd., Eli Lilly and Company, GLAXOSMITHKLINE PLC, Johnson & Johnson, Julphar, MannKind Corporation, Medtronic PLC, Merck & Co., Novartis International AG, Novo Nordisk A/S, Oramed Pharmaceuticals, Pfizer Inc., Piramal Healthcare, Sanofi SA, Teijin Limited, Tonghua Dongbao Pharmaceutical Co., Ltd, US Vitamins Limited, Wockhardt Ltd, and Ypsomed AG.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Insulin Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Insulin Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Insulin Market?
4. What is the competitive strategic window for opportunities in the Global Insulin Market?
5. What are the technology trends and regulatory frameworks in the Global Insulin Market?
6. What is the market share of the leading vendors in the Global Insulin Market?
7. What modes and strategic moves are considered suitable for entering the Global Insulin Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Adocia
  • Biocon Limited
  • Eli Lilly and Company
  • Julphar
  • Merck & Co.
  • Oramed Pharmaceuticals
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Drug Outlook
3.4. Application Outlook
3.5. Region Outlook
3.6. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of diabetes among the population
5.1.1.2. Increasing incidence of geriatric and obese population
5.1.1.3. Rapid development in insulin delivery systems, drug, and analog development
5.1.2. Restraints
5.1.2.1. High cost associated with insulin drugs
5.1.3. Opportunities
5.1.3.1. New regulations for insulin biosimilars and rising investments in R&D
5.1.3.2. High potential of insulin drug in emerging economies
5.1.4. Challenges
5.1.4.1. Strict regulatory norms for the approval of product
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Insulin Market, by Drug
6.1. Introduction
6.2. Biologic
6.3. Biosimilar

7. Insulin Market, by Application
7.1. Introduction
7.2. Type I Diabetes
7.3. Type II Diabetes

8. Americas Insulin Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Insulin Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Thailand

10. Europe, Middle East & Africa Insulin Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Adocia
12.2. AstraZeneca PLC
12.3. B. Braun Melsungen AG
12.4. Becton, Dickinson and Company
12.5. Biocon Limited
12.6. Biodel Inc.
12.7. Bioton SA
12.8. Dongbao Enterprise Group Co., Ltd.
12.9. Eli Lilly and Company
12.10. GLAXOSMITHKLINE PLC
12.11. Johnson & Johnson
12.12. Julphar
12.13. MannKind Corporation
12.14. Medtronic PLC
12.15. Merck & Co.
12.16. Novartis International AG
12.17. Novo Nordisk A/S
12.18. Oramed Pharmaceuticals
12.19. Pfizer Inc.
12.20. Piramal Healthcare
12.21. Sanofi SA
12.22. Teijin Limited
12.23. Tonghua Dongbao Pharmaceutical Co., Ltd
12.24. US Vitamins Limited
12.25. Wockhardt Ltd
12.26. Ypsomed AG

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL INSULIN MARKET SIZE, 2020 VS 2026 (USD BILLION)
FIGURE 2. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2020 (USD BILLION)
FIGURE 3. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2020 (USD BILLION)
FIGURE 4. GLOBAL INSULIN MARKET SIZE, BY REGION, 2020 (USD BILLION)
FIGURE 5. GLOBAL INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 6. GLOBAL INSULIN MARKET: MARKET DYNAMICS
FIGURE 7. GLOBAL INSULIN MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 8. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2020 VS 2026 (%)
FIGURE 9. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2020 VS 2026 (USD BILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL INSULIN MARKET SIZE, BY DRUG, 2026
FIGURE 11. GLOBAL INSULIN MARKET SIZE, BY BIOLOGIC, 2018-2026 (USD BILLION)
FIGURE 12. GLOBAL INSULIN MARKET SIZE, BY BIOLOGIC, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 13. GLOBAL INSULIN MARKET SIZE, BY BIOSIMILAR, 2018-2026 (USD BILLION)
FIGURE 14. GLOBAL INSULIN MARKET SIZE, BY BIOSIMILAR, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 15. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2020 VS 2026 (%)
FIGURE 16. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2020 VS 2026 (USD BILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2026
FIGURE 18. GLOBAL INSULIN MARKET SIZE, BY TYPE I DIABETES, 2018-2026 (USD BILLION)
FIGURE 19. GLOBAL INSULIN MARKET SIZE, BY TYPE I DIABETES, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 20. GLOBAL INSULIN MARKET SIZE, BY TYPE II DIABETES, 2018-2026 (USD BILLION)
FIGURE 21. GLOBAL INSULIN MARKET SIZE, BY TYPE II DIABETES, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 22. AMERICAS INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 23. ARGENTINA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 24. BRAZIL INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 25. CANADA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 26. MEXICO INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 27. UNITED STATES INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 28. ASIA-PACIFIC INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 29. AUSTRALIA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 30. CHINA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 31. INDIA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 32. INDONESIA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 33. JAPAN INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 34. MALAYSIA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 35. PHILIPPINES INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 36. SINGAPORE INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 37. SOUTH KOREA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 38. THAILAND INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 39. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 40. FRANCE INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 41. GERMANY INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 42. ITALY INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 43. NETHERLANDS INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 44. QATAR INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 45. RUSSIA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 46. SAUDI ARABIA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 47. SOUTH AFRICA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 48. SPAIN INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 49. UNITED ARAB EMIRATES INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 50. UNITED KINGDOM INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 51. GLOBAL INSULIN MARKET: FPNV POSITIONING MATRIX
FIGURE 52. GLOBAL INSULIN MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 53. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL INSULIN MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL INSULIN MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 4. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 5. GLOBAL INSULIN MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2026 (USD BILLION)
TABLE 6. GLOBAL INSULIN MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2026 (USD BILLION)
TABLE 7. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 8. GLOBAL INSULIN MARKET SIZE, BY TYPE I DIABETES, BY REGION, 2018-2026 (USD BILLION)
TABLE 9. GLOBAL INSULIN MARKET SIZE, BY TYPE II DIABETES, BY REGION, 2018-2026 (USD BILLION)
TABLE 10. AMERICAS INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 11. ARGENTINA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 12. BRAZIL INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 13. CANADA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 14. MEXICO INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 15. UNITED STATES INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 16. ASIA-PACIFIC INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 17. AUSTRALIA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 18. CHINA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 19. INDIA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 20. INDONESIA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 21. JAPAN INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 22. MALAYSIA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 23. PHILIPPINES INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 24. SINGAPORE INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 25. SOUTH KOREA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 26. THAILAND INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 27. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 28. FRANCE INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 29. GERMANY INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 30. ITALY INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 31. NETHERLANDS INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 32. QATAR INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 33. RUSSIA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 34. SAUDI ARABIA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 35. SOUTH AFRICA INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 36. SPAIN INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 37. UNITED ARAB EMIRATES INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 38. UNITED KINGDOM INSULIN MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 39. GLOBAL INSULIN MARKET: SCORES
TABLE 40. GLOBAL INSULIN MARKET: BUSINESS STRATEGY
TABLE 41. GLOBAL INSULIN MARKET: PRODUCT SATISFACTION
TABLE 42. GLOBAL INSULIN MARKET: RANKING
TABLE 43. GLOBAL INSULIN MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 44. GLOBAL INSULIN MARKET: MERGER & ACQUISITION
TABLE 45. GLOBAL INSULIN MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 46. GLOBAL INSULIN MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 47. GLOBAL INSULIN MARKET: INVESTMENT & FUNDING
TABLE 48. GLOBAL INSULIN MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 49. GLOBAL INSULIN MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Adocia
  • AstraZeneca PLC
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Biocon Limited
  • Biodel Inc.
  • Bioton SA
  • Dongbao Enterprise Group Co., Ltd.
  • Eli Lilly and Company
  • GLAXOSMITHKLINE PLC
  • Johnson & Johnson
  • Julphar
  • MannKind Corporation
  • Medtronic PLC
  • Merck & Co.
  • Novartis International AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals
  • Pfizer Inc.
  • Piramal Healthcare
  • Sanofi SA
  • Teijin Limited
  • Tonghua Dongbao Pharmaceutical Co., Ltd
  • US Vitamins Limited
  • Wockhardt Ltd
  • Ypsomed AG
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll